

Gibson Dunn Advises Natera on Acquisition of Foresight Diagnostics

Firm News | December 5, 2025

Gibson Dunn advised Natera, Inc., a global leader in cell-free DNA and precision medicine, on its acquisition of Foresight Diagnostics, a leader in ultrasensitive molecular residual disease detection. Our corporate team included partners Branden Berns, Gina Hancock, and Jin Hee Kim.

Related People

[Branden C. Berns](#)

[Gina Hancock](#)

[Jin Hee Kim](#)

Related Capabilities

[Mergers and Acquisitions](#)

[Life Sciences](#)